Nanoparticle-based cancer therapies: Albumin-bound paclitaxel
Record ID 32010000995
English
Authors' objectives:
Nanoparticle-albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) is a chemotherapeutic drug that is administered alone or in combination with other agents for the purpose of delaying disease progression and prolonging survival in patients who have cancer. Nab-paclitaxel differs from standard paclitaxel in that it is a colloidal suspension of 130-nanometer (nm) albumin-bound nanoparticles of paclitaxel and is, therefore, free of solvents. The goal of this new nanotechnology based formulation is to reduce toxicity and improve the bioavailability of paclitaxel.
Details
Project Status:
Completed
URL for project:
http://www.hayesinc.com
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Nanomedicine
- Nanoparticles
- Neoplasms
- Paclitaxel
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2010 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.